Company intelligence / Profile preview

Yuanpin Cell Biotechnology

Changsha, Hunan, China

Ownership: Private
Development stage: Other

Overview

Yuanpin Cell Biotechnology has developed clinical-grade stem cell products (notably amnion and umbilical cord mesenchymal stem cells), with clinical trial applications accepted for their therapies, but full trial outcomes are not yet published

Therapeutic areas: Neurology
Modalities: Cell therapyStem cell therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

human amniotic mesenchymal stem cells

Partnerships

Jiangsu Provincial People's HospitalUniversity of Pittsburgh, USASecond Affiliated Hospital of Nanhua UniversityTongji University, ShanghaiHunan Normal University

Beyond the preview

Go deeper on Yuanpin Cell Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuanpin Cell Biotechnology.

Explore the full profile